Neogap receives CTA approval for a phase I/IIa clinical trial with its advanced cell therapy
Neogap Therapeutics today announces that the Swedish Medical Products Agency has approved the company's application to start a clinical trial of its personalised cell therapy against colorectal cancer. The phase I/IIa trial is planned to be initiated during the first half of 2023.Neogap's cell therapy product pTTL (personalised Tumor Trained Lymphocytes) is a unique immunotherapy that aims to treat solid tumors by training the immune system to recognize neoantigens and thereby attack the cancer. A neoantigen is an altered protein only found in the tumor after a mutation has occurred in a